» Articles » PMID: 35117970

Animal Models for SARS-CoV-2 and SARS-CoV-1 Pathogenesis, Transmission and Therapeutic Evaluation

Overview
Journal World J Virol
Date 2022 Feb 4
PMID 35117970
Authors
Affiliations
Soon will be listed here.
Abstract

There is a critical need to develop animal models to alleviate vaccine and drug development difficulties against zoonotic viral infections. The coronavirus family, which includes severe acute respiratory syndrome coronavirus 1 and severe acute respiratory syndrome coronavirus 2, crossed the species barrier and infected humans, causing a global outbreak in the 21 century. Because humans do not have pre-existing immunity against these viral infections and with ethics governing clinical trials, animal models are therefore being used in clinical studies to facilitate drug discovery and testing efficacy of vaccines. The ideal animal models should reflect the viral replication, clinical signs, and pathological responses observed in humans. Different animal species should be tested to establish an appropriate animal model to study the disease pathology, transmission and evaluation of novel vaccine and drug candidates to treat coronavirus disease 2019. In this context, the present review summarizes the recent progress in developing animal models for these two pathogenic viruses and highlights the utility of these models in studying SARS-associated coronavirus diseases.

Citing Articles

Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme.

Varghese A, Liu J, Liu B, Guo W, Dong F, Patterson T Molecules. 2025; 30(3).

PMID: 39942596 PMC: 11820935. DOI: 10.3390/molecules30030491.


Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice.

Singh G, Diego J, Warang P, Park S, Chang L, Noureddine M Nat Commun. 2024; 15(1):10178.

PMID: 39580470 PMC: 11585546. DOI: 10.1038/s41467-024-54334-7.


Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.

Zheng H, Song T, Zheng Y Zool Res. 2024; 45(4):747-766.

PMID: 38894519 PMC: 11298684. DOI: 10.24272/j.issn.2095-8137.2024.062.


The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects.

Collins C, Longo D, Murphy W Front Immunol. 2024; 15:1345499.

PMID: 38469293 PMC: 10925677. DOI: 10.3389/fimmu.2024.1345499.


Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population.

Cruz Cisneros M, Anderson E, Hampton B, Parotti B, Sarkar S, Taft-Benz S Vaccines (Basel). 2024; 12(1).

PMID: 38276675 PMC: 10821422. DOI: 10.3390/vaccines12010103.


References
1.
Bhatia H, Singh H, Grewal N, Natt N . Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014; 5(4):278-84. PMC: 4231565. DOI: 10.4103/0976-500X.142464. View

2.
Bukreyev A, Lamirande E, Buchholz U, Vogel L, Elkins W, St Claire M . Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004; 363(9427):2122-7. PMC: 7112367. DOI: 10.1016/S0140-6736(04)16501-X. View

3.
Gu H, Chen Q, Yang G, He L, Fan H, Deng Y . Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020; 369(6511):1603-1607. PMC: 7574913. DOI: 10.1126/science.abc4730. View

4.
Garcia-Arriaza J, Esteban M, Lopez D . Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines. 2021; 9(9). PMC: 8466845. DOI: 10.3390/biomedicines9091122. View

5.
Letko M, Marzi A, Munster V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020; 5(4):562-569. PMC: 7095430. DOI: 10.1038/s41564-020-0688-y. View